.Pharmacolibrary.Drugs.ATC.L.L01EX18 .Pharmacolibrary.Drugs.ATC.L.L01EX18| name: | Avapritinib |
| ATC code: | L01EX18 | route: | oral |
| n-compartments | 2 |
Avapritinib is a tyrosine kinase inhibitor that selectively inhibits KIT and PDGFRA mutant kinases. It is primarily used for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a PDGFRA exon 18 mutation, including D842V mutations. Avapritinib was approved by the US FDA in 2020 for this indication.
Pharmacokinetic parameters in adult patients with unresectable or metastatic GIST after oral administration of avapritinib under fasting conditions.
Yue, Z, et al., & Sheng, Y (2024). Evaluation of Bioequivalence for Avapritinib Tablets in Chinese Participants Under Fasting Conditions Using a Reference-Scaled Average Bioequivalence Method. Clinical pharmacology in drug development 13(6) 672–676. DOI:10.1002/cpdd.1398 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38523571